RxSight, Inc. (NASDAQ:RXST) Shares Acquired by Baillie Gifford & Co.

Baillie Gifford & Co. increased its stake in shares of RxSight, Inc. (NASDAQ:RXST) by 17.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 419,004 shares of the company’s stock after acquiring an additional 60,789 shares during the quarter. Baillie Gifford & Co. owned about 1.13% of RxSight worth $20,711,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of RXST. CWM LLC increased its position in shares of RxSight by 727.5% during the second quarter. CWM LLC now owns 422 shares of the company’s stock worth $25,000 after purchasing an additional 371 shares in the last quarter. Nisa Investment Advisors LLC grew its stake in RxSight by 854.1% during the 3rd quarter. Nisa Investment Advisors LLC now owns 582 shares of the company’s stock worth $29,000 after buying an additional 521 shares during the last quarter. Quest Partners LLC purchased a new stake in RxSight in the second quarter valued at approximately $41,000. Amalgamated Bank lifted its stake in RxSight by 21.3% in the second quarter. Amalgamated Bank now owns 1,177 shares of the company’s stock valued at $71,000 after buying an additional 207 shares during the last quarter. Finally, Canada Pension Plan Investment Board acquired a new stake in shares of RxSight in the second quarter valued at approximately $156,000. 78.78% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. Jefferies Financial Group started coverage on shares of RxSight in a research report on Tuesday, October 29th. They issued a “buy” rating and a $72.00 price target for the company. Oppenheimer reduced their target price on shares of RxSight from $72.00 to $65.00 and set an “outperform” rating for the company in a report on Tuesday, August 6th. Stifel Nicolaus lowered their price target on RxSight from $70.00 to $65.00 and set a “buy” rating on the stock in a report on Tuesday, August 6th. Needham & Company LLC reaffirmed a “buy” rating and set a $66.00 price objective on shares of RxSight in a research note on Friday, September 13th. Finally, Wells Fargo & Company decreased their price objective on RxSight from $68.00 to $54.00 and set an “overweight” rating for the company in a research report on Tuesday, August 6th. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat.com, RxSight presently has a consensus rating of “Buy” and an average price target of $61.63.

Insider Transactions at RxSight

In related news, insider Ilya Goldshleger sold 3,100 shares of the company’s stock in a transaction on Friday, October 4th. The stock was sold at an average price of $48.01, for a total transaction of $148,831.00. Following the transaction, the insider now owns 42,246 shares of the company’s stock, valued at $2,028,230.46. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. In the last three months, insiders sold 43,415 shares of company stock valued at $2,178,847. Corporate insiders own 9.36% of the company’s stock.

RxSight Stock Performance

Shares of NASDAQ:RXST opened at $45.46 on Wednesday. The company has a 50-day moving average price of $50.85 and a 200 day moving average price of $53.46. RxSight, Inc. has a 52 week low of $25.14 and a 52 week high of $66.54.

RxSight Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.